Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 16/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 16/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 16/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 15/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 14/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 14/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 9/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369769 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| Hydrochloric Acid SCHEMBL19694788 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL9838934 | 0.91 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL7552127 | 0.89 | GABRA1 (0.80) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL9083956 | 0.88 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL22680192 | 0.88 | GABRA1 (0.79) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL22680193 | 0.84 | GABRA1 (0.79) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL7378648 | 0.84 | GABRA1 (0.84) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL9584197 | 0.83 | GABRA1 (0.71) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL7381277 | 0.82 | GABRA1 (0.70) | GABRA1GABRA5GABRA3GABRA2GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527799-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2026-01-20 | — | — | US | disclosed |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | DRAIG THERAPEUTICS LTD (GB) | 2024-12-26 | — | — | US | disclosed |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2024-06-27 | — | — | US | disclosed |
| EP-3054934-B1 | METHODS AND COMPOSITIONS FOR TREATING WITHDRAWAL SYNDROMES USING NON-SEDATIVE DEXMEDETOMIDINE TRANSDERMAL COMPOSITIONS | TEIKOKU PHARMA USA INC (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024055118-A1 | USE OF MINOR CANNABINOIDS IN THE TREATMENT OF SEIZURE DISORDERS | CANNABIS ORCHARDS INC. (CA) | 2024-03-21 | — | — | WO | disclosed |
| EP-4334301-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | University College Cardiff Consultants Limited (GB) | 2024-03-13 | — | — | EP | disclosed |
| US-20230346809-A1 | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) | 2023-11-02 | — | — | US | disclosed |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2023-09-12 | — | — | US | disclosed |
| CN-116234580-A | Use of cannabidiol in the treatment of seizures associated with rare epileptic syndromes associated with genetic abnormalities | 吉伟研究有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-02-09 | — | — | US | disclosed |
| EP-0216555-B1 | USE OF DIOXOPIPERIDINE DERIVATIVES IN THE TREATMENT OF ANXIETY, FOR THE REDUCTION OF CHRONIC ABNORMALLY HIGH BRAIN LEVELS OF SEROTONIN OR 5-HYDROXY-INDOLEACETIC ACID, AND IN THE TREATMENT OF BACTERIAL OR VIRAL INFECTIONS | BTG INTERNATIONAL LIMITED (GB) | 1992-09-02 | — | — | EP | disclosed |
| US-5100906-A | 5-ARYL-4-ALKYL-3H-1,2,4-TRIAZOLE-3-THIONES USEFUL AS MEMORY ENHANCERS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-03-31 | — | — | US | disclosed |
| EP-0452926-A2 | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers | MERRELL PHARMACEUTICALS INC. (US) | 1991-10-23 | — | — | EP | disclosed |
| EP-0452765-A2 | Pharmaceutical composition and medical uses of dioxopiperidine derivatives, especially as immune response potentiators, antiviral and antibacterial agents | BTG INTERNATIONAL LIMITED (GB) | 1991-10-23 | — | — | EP | disclosed |
| US-4994475-A | Treating anxiety with dioxopiperidines; bacterial and viral infections | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-02-19 | — | — | US | disclosed |
| US-4918084-A | ANXIOLYTIC AGENTS; BENZODIAZEPINE INVERSE AGONIST ANTAGONISTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-04-17 | — | — | US | disclosed |
| US-4894377-A | ANTICONVULSANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-01-16 | — | — | US | disclosed |
| US-4835151-A | ANXIOLYTIC AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-05-30 | — | — | US | disclosed |
| US-4738973-A | ANXIOLYTIC AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1988-04-19 | — | — | US | disclosed |
| EP-0216555-A2 | Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections | BTG INTERNATIONAL LIMITED (GB) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | NLN, GLS, PRNP | GABRA1 4456/4885GABRA5 4417/4885GABRA3 4541/4885 |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | GABRA5, GABRB3, GABRA3 | GABRA1 7/4885GABRA5 1/4885GABRA3 3/4885 |
| US-12527799-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2C, GRIN3A, GRIN1 | GABRA1 13/4885GABRA5 37/4885GABRA3 17/4885 |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | GABRA1 18/4885GABRA5 30/4885GABRA3 22/4885 |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | GABRA1 18/4885GABRA5 30/4885GABRA3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.